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Abstract
Background:Slight changes in the lipid proﬁle can be observed over the acute phase of infectious diseases. Moreover, some anti-
infective drugs can modify serum lipid concentrations, although antibiotics do not seem to have a relevant, direct, or acute effect on
the lipid proﬁle.
Methods:A 75-day-old breastfed Caucasian female, born at term after a regular pregnancy, was hospitalized for osteomyelitis. She
was immediately treated with intravenous meropenem and vancomycin. Therapy was effective, but after 22 days of treatment, her
blood was found to be viscous with a purple shade.
Results: A fasting blood sample showed serum triglycerides of 966mg/dL, total cholesterol of 258mg/dL, and high-density
lipoprotein cholesterol of 15mg/dL. Secondary causes of hyperlipidemia and primary hereditary disorders were ruled out. Thereafter,
the possibility that antibiotics may have had a role in the hypertriglyceridemia was considered, and meropenem was discontinued.
After 72 hours of meropenem discontinuation, a sharp modiﬁcation of lipid variables was observed, and further testing showed a
complete normalization of the lipid proﬁle.
Conclusion: In this child with osteomyelitis, the increase in serum triglycerides appeared suddenly after 3 weeks of meropenem
treatment and resolved quickly after meropenem discontinuation, thus highlighting the possible association between meropenem
and lipid proﬁle alterations. Monitoring the lipid proﬁle should be considered in cases of long-term treatment with meropenem, and
further studies on meropenem safety should include evaluation of the lipid proﬁle.
Abbreviations: HDL = high-density lipoprotein, WBC = white blood cell count.
Keywords: antibiotics, hyperlipidemia, hypertriglyceridemia, meropenem, osteomyelitis
1. Introduction part of a general metabolic response to infections. In general,For several years, it has been known that changes in the lipid
proﬁle can be observed over the course of infectious diseases asEditor: Fadi Khasawneh.
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1during severe acute infection, serum concentrations of total
cholesterol and high-density lipoprotein (HDL) cholesterol are
reduced, whereas the serum concentrations of triglycerides are
increased.[1–3] However, the serum levels of all these parameters
are usually only slightly modiﬁed and tend to normalize with
healing after the acute phase of the disease. Moreover, some
anti-infective drugs can modify serum lipid concentrations. The
best example of this is represented by some highly active
antiretroviral drugs that are currently administered to adults
and children to treat HIV infection.[4] Although it has been
recently demonstrated that the early use of antibiotics in the
prenatal and postnatal period can inﬂuence lipid metabolism
trough alterations of the intestinal microbiome,[5] no relevant,
direct, or acute effect on the lipid proﬁle has been demonstrated.
This paper reports a case of a young infant suffering from
osteomyelitis who developed transient serum lipid alterations
strictly associated with the administration of the recommended
doses of meropenem.2. Case
2.1. Presenting concerns
A 75-day-old Caucasian female born at term after a regular
pregnancy, with weight and length within the normal range, was
admitted to the emergency room with fever (maximal axillary
temperature, 39.0 °C), irritability, and poor feeding.
[6,7]
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Her medical and family histories were negative, and she did not
have any comorbidities.
She had a septic appearance (i.e., axillary temperature 39 °C,
gray color, lethargy, and feeding intolerance) and showed
evidence of a subcutaneous soft tissue mass overlying the middle
and lower sternum and adjacent ribs on the left side.
Laboratory ﬁndings showed severe anemia (hemoglobin,
6.8g/dL), a signiﬁcantly increased white blood cell count
(WBC; 32,000/mm3) with neutrophilia (65%), and a marked
increase in both C-reactive protein and procalcitonin serum
concentrations (17.6mg/dL and 1.23mg/dL, respectively).
Magnetic resonance imaging conﬁrmed the diagnosis of rib
osteomyelitis.
The infant, who continued to receive breast milk and did not
receive any parenteral nutrition, was immediately treated with
intravenous meropenem (100mg/kg/d in 3 divided doses) and
vancomycin (40mg/kg/d in 3 divided doses). Meropenem dosage
was the same recommended for meningitis due to the infant’s
septic conditions. Whole blood transfusion was initially added to
eliminate anemia and restore normal circulation.
Therapy was rapidly effective. There was an evident improve-
ment in her general clinical condition after a few days. After 1
week, hemoglobin returned to within normal range, and the
WBC and acute phase reactant serum concentrations returned to
normal.
After 22 days of treatment, when a venous sample was drawn
for laboratory controls, the blood was found slightly lactescent as
nonfat skim milk. The following day, a fasting blood sample was
obtained again. After centrifugation, triglycerides in the serum
were 966mg/dL, total cholesterol was 258mg/dL, and HDL
cholesterol was 15mg/dL.2.3. Timeline
Table 1 summarizes the main clinical and laboratory ﬁndings in
this 75-day-old infant with a diagnosis of osteomyelitis treated
with meropenem and vancomycin.
Management of this case and its publication were approved by
the Ethics Committee of Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy. Written informed
consent was obtained from the patient’s parents.
2.4. Diagnostic focus and assessment
Further lipid proﬁle testing during the following days revealed
similar values. The mother was instructed to breastfeed in
sessions at least 4 hours apart, and blood samples were always
obtained after 4 hours of fasting.
Secondary causes of hyperlipidemia, such as diabetes mellitus,
hypothyroidism, renal failure, glycogen storage disease, lipodys-
trophy, lymphoma, systemic lupus erythematosus, and HIV
infection, were ruled out.
Laboratory tests of the parents excluded primary hereditary
disorders, including familial dyslipidemias.2.5. Therapeutic focus and assessment
Because the lipidproﬁle remainedabnormal despite a normalWBC
and acute phase reactants, the possibility was considered that
antibioticsmight have had a role in this adverse event.On the basis
of data highlighting the role ofmethicillin-resistant Staphylococcus
aureus as the main etiologic agent of osteomyelitis in the ﬁrst years2of life, even if in absence of blood culture positivity in this
initially septic infant, it was decided to stop meropenem and
continue vancomycin.
After 72 hours of meropenem discontinuation, a sharp
modiﬁcation of the previously abnormal lipid variables was
evident. Serum triglycerides were 152mg/dL, total cholesterol
215mg/dL, and HDL cholesterol 27mg/dL.2.6. Follow-up and outcomes
Italian government pharmacovigilance agency was immediately
informed on the adverse event possibly related tomeropenem use,
and then the government agency informed the drug manufactur-
er. Vancomycin was stopped after 2 additional weeks. At the end
of therapy and after 1month, there was a complete normalization
of the lipid proﬁle, and laboratory test results were normal.3. Discussion
In this child with osteomyelitis, a transient, relevant modiﬁcation
of the concentration of serum triglycerides was evident. The
triglycerides were found to be up to 5 times higher than the
maximum normal level of subjects of the same age and similar
feeding pattern, whereas total cholesterol was increased and
HDL cholesterol decreased. The increase in serum triglycerides
appeared suddenly after almost 3 weeks of meropenem treatment
and resolved quickly after meropenem discontinuation.
The clinical feature, especially the sudden onset and rapid
ascent of serum triglycerides to well above the normal levels,
excludes familial dyslipidemias.[8] These diseases were also
excluded by the examinations performed in the infant and her
parents and by the lipid proﬁle’s rapid return to normal. A
mutation in theGPD1 gene, which encodes glycerol-3-phosphate
dehydrogenase 1, is associated with moderate-to-severe transient
hypertriglyceridemia in infancy that normalizes with age.[9]
However, in these cases, normalization occurs after years during
late childhood or early adulthood. In addition, both the
triglycerides and total cholesterol levels in the parents were
found to be within normal limits, further supporting this
conclusion.
Serum lipids can be derived from food and be transported from
the gut to the bloodstream. A high-saturated fat diet can cause
serum lipid alterations.[8] However, the child was always
breastfed and did not receive any intravenous lipid intake during
the hospital stay. As previously reported, infections can be
associated with mild-to-moderate changes in the lipid proﬁle, but
these variations usually begin in the early phase of the infectious
disease as part of the whole picture leading to an increased
synthesis of acute phase proteins, although they can persist
during the convalescent phase.[10] In this child, the triglyceride
changes were severe and occurred only after 3 weeks from the
disease onset, a result suggesting no relationship with the
osteomyelitis. In contrast, the lipid proﬁle changes were
apparently associated with meropenem administration and
rapidly resolved after the antibiotic was withdrawn.
Meropenem is a carbapenem antibiotic that is approved for the
treatment of complicated skin and skin structure infections,
complicated intra-abdominal infections, and pediatric bacterial
meningitis in patients ≥3 months. However, meropenem is often
prescribed off-label in neonates and younger infants who suffer
from severe life-threatening supposed bacterial infections[11] and
at doses in the range of those suggested for treatment of
meningitis in older children,[12] as occurred in this case. The
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4safety proﬁle of meropenem has been studied in the past both in
adults and in children.[12–15] The drug has been found to be safe
and well tolerated because no more than 3% of exposed subjects
experience a drug-related adverse event.[13] The gastrointestinal
tolerability was considered excellent, and no risk of seizure,
previously evidenced with other carbapenems, was demonstrat-
ed. Moreover, changes in the levels of biochemical markers,
including indicators of renal[13] and hepatic injury,[14] have never
been reported, even in subjects with renal or liver disease.
However, all of these data have been collected in patients older
than 3 months, and variability related to an infant’s development
is absent. A study to solve this problem and clarify the safety of
meropenem in the ﬁrst 3 months of life is in progress.[15] This is
the ﬁrst report of transient hypertriglyceridemia associated with
meropenem, and previous studies did not show an inﬂuence on
lipid proﬁle associated with meropenem use. Although it is not
possible to understand from a single case insights on how
meropenem administration caused hypertriglyceridemia, this
case highlights that monitoring the lipid proﬁle should be
considered in cases of long-term treatment with meropenem, and
further studies on the safety of meropenem should include
evaluation of serum triglycerides and cholesterol.
4. Patient’s parents’ perspective
Wewere very worried whenwewere informed of the alteration in
our baby’s lipid proﬁle. In particular, we were worried about the
possibility that something was wrong with breastfeeding. We
were conﬁdent in the pediatricians who followed our child, and
we were very happy to discover that the lipid proﬁle had returned
to normal a few days after discontinuing meropenem.
5. Informed consent
The patient’s parents provided their written informed consent for
the publication of this study.
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